Bevacizumab for metastatic renal cell carcinoma: A monoclonal antibody in a sea of small molecules

Expert Opinion on Biological Therapy

Volumn 10, Issue 11, 2010, Pages 1517-1520

  Pal, Sumanta Kumar ^a   Figlin, Robert A ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB;

CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; KIDNEY CARCINOMA; MEDICAL SPECIALIST; METASTASIS; ONCOLOGY; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; REVIEW;

ANTIBODIES, MONOCLONAL; BENZENESULFONATES; CARCINOMA, RENAL CELL; CLINICAL TRIALS, PHASE III AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; INTERFERON-ALPHA; KIDNEY NEOPLASMS; MULTICENTER STUDIES AS TOPIC; PYRIDINES; PYRIMIDINES; PYRROLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SIROLIMUS; SULFONAMIDES; SURVIVAL ANALYSIS;

EID: 77958501455     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2010.522904     Document Type: Review

References (30)

1. Sandler A, Gray R, Perry MC, et al.. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-2550
2. Hurwitz H, Fehrenbacher L, Novotny W, et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
3. NCCN Practice Guidelines in Oncology (v.1.2010): Colon cancer Available from: http://www.nccn.org [Last accessed 22 July 2010]
4. Miller K, Wang M, Gralow J, et al.. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666-2676
5. Vredenburgh JJ, Desjardins A, Herndon JE II, et al.. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 2007;25:4722-4729
6. Escudier B, Bellmunt J, Negrier S, et al.. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010;28:2144-2150
7. FDA Approval for Bevacizumab. Available from: http://www.cancer.gov/ cancertopics/druginfo/fda-bevacizumab [Last accessed 23 July 2010]
8. Rini BI, Halabi S, Rosenberg JE, et al.. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28:2137-2143
9. Rini BI, Halabi S, Rosenberg JE, et al.. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 2008;26:5422-5428
10. National Comprehensive Cancer Network Clinical Practice Guidelines: renal cell carcinoma Available from: http://www.nccn.org [Last accessed 23 July 2010]
11. Hudes G, Carducci M, Tomczak P, et al.. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-2281
12. Sternberg CN, Davis ID, Mardiak J, et al.. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J Clin Oncol 2010;28:1061-1068
13. Mickisch GH, Schwander B, Escudier BJ, et al.. Indirect comparison of bevacizumab plus interferon-alpha-2a versus tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy. J Clin Oncol (Meeting Abstracts) 2010;28:4612
14. NCT00720941: Study VEG108844, a Study of Pazopanib Versus Sunitinib in the treatment of subjects with locally advanced and/or metastatic renal cell carcinoma Available from: http://www.clinicaltrials.gov [Accessed 22 December 2009
15. NCT00631371: Phase 3b, Randomized, Open-Label Study of bevacizumab + temsirolimus ) vs bevacizumab + interferon-alfa as first-line treatment in subjects with advanced renal cell carcinoma. Available from: http://www.clinicaltrials.gov [Last accessed 29 March 2010]
16. NCT00378703: The BeST Trial: a randomized phase II study of VEGF, RAF Kinase, and mTOR combination rargeted rherapy (CTT) with bevacizumab, sorafenib and temsirolimus in advanced renal cell carcinoma [BeST] Available from: http://www.clinicaltrials. gov [Accessed 22 December 2009]
17. NCT00719264: a randomized, open-label, multi-center Phase II study to compare bevacizumab plus RAD001 versus interferon alfa-2a plus bevacizumab for the first-line treatment of patients with metastatic clear cell carcinoma of the kidney. Available from: http://www.clinicaltrials.gov [Accessed 22 December 2009]
18. Escudier BJ, Negrier S, Gravis G, et al.. Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial. J Clin Oncol (Meeting Abstracts) 2010;28:4516
19. Burstein HJ, Chen Y-H, Parker LM, et al.. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008;14:7871-7877
20. Schultheis AM, Lurje G, Rhodes KE, et al.. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008;14:7554-7563
21. Schneider BP, Wang M, Radovich M, et al.. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 2008;26:4672-4678
22. Gordan JD, Lal P, Dondeti VR, et al.. HIF-[alpha] Effects on c-Myc distinguish two subtypes of sporadic vhl-deficient clear cell renal carcinoma. Cancer Cell 2008;14:435-446
23. Brannon AR, Reddy A, Seiler M, et al.. Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns. Genes Cancer 2010;1:152-163
24. Escudier BJ, Ravaud A, Negrier S, et al.. Update on AVOREN trial in metastatic renal cell carcinoma (mRCC): efficacy and safety in subgroups of patients (pts) and pharmacokinetic (PK) analysis. J Clin Oncol (Meeting Abstracts) 2008;26:5025
25. Choueiri TK, Xie W, Kollmannsberger CK, et al.. The impact of body mass index (BMI) and body surface area (BSA) on treatment outcome to vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma: results from a large international collaboration. J Clin Oncol (Meeting Abstracts) 2010;28:4524
26. Heng DYC, Xie W, Regan MM, et al.. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009;27:5794-5799
27. Dial E, Duh M, Fournier A, et al.. Cost implications of intravenous bevacizumab treatment in patients with renal cell carcinoma (RCC): a retrospective claims database analysis. J Clin Oncol (Meeting Abstracts) 2009;27:5112
28. Bukowski RM, Kabbinavar FF, Figlin RA, et al.. Randomized Phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 2007;25:4536-4541
29. Yang JC, Haworth L, Sherry RM, et al.. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349:427-434
30. FDA advisory committee recommends against bevacizumab for metastatic breast cancer Available from: http://www. cancer.gov/ncicancerbulletin/072710/ page2 [Last accessed 28 July 2010]